Abstract b1-Integrins are essential for angiogenesis. The mechanisms regulating integrin function in endothelial cells (EC) and their contribution to angiogenesis remain elusive. Brag2 is a guanine nucleotide exchange factor for the small Arf-GTPases Arf5 and Arf6. The role of Brag2 in EC and angiogenesis and the underlying molecular mechanisms remain unclear. siRNA-mediated Brag2-silencing reduced EC angiogenic sprouting and migration. Brag2-siRNA transfection differentially affected a5b1-and aVb3-integrin function: specifically, Brag2-silencing increased focal/fibrillar adhesions and adhesion on b1-integrin ligands (fibronectin and collagen), while reducing the adhesion on the aVb3-integrin ligand, vitronectin. Consistent with these results, Brag2-silencing enhanced surface expression of a5b1-integrin, while reducing surface expression of aVb3-integrin. Mechanistically, Brag2-mediated aVb3-integrin-recycling and b1-integrin endocytosis and specifically of the active/matrix-bound a5b1-integrin present in fibrillar/focal adhesions (FA), suggesting that Brag2 contributes to the disassembly of FA via b1-integrin endocytosis. Arf5 and Arf6 are promoting downstream of Brag2 angiogenic sprouting, b1-integrin endocytosis and the regulation of FA. In vivo silencing of the Brag2-orthologues in zebrafish embryos using morpholinos perturbed vascular development. Furthermore, in vivo intravitreal injection of plasmids containing Brag2-shRNA reduced pathological ischemia-induced retinal and choroidal neovascularization. These data reveal that Brag2 is essential for developmental and pathological angiogenesis by promoting EC sprouting through regulation of adhesion by mediating b1-integrin internalization and link for the first time the process of b1-integrin endocytosis with angiogenesis.
Introduction
Angiogenesis, the formation of new capillaries from preexisting ones by endothelial cell (EC) sprouting, is involved in many physiologic and pathologic conditions, including embryonic development, wound healing, rheumatoid arthritis, tumor growth and metastasis and proliferative retinopathy [5] . Beyond endothelial cells also proangiogenic cells circulating in blood contribute to angiogenesis by paracrine effects [28, 32] .
Integrins are heterodimeric transmembrane proteins consisting of non-covalent bound a-and b-subunits mediating cell adhesion to extracellular matrix (ECM) proteins and bidirectional signaling [24] . Beyond angiogenic growth factors, there is evidence that integrins are implicated in angiogenesis [23] . Specifically, endothelialrestricted deficiency of b1-integrins and of the a5-integrin subunit of the b1-integrins impairs in vivo angiogenesis [4, 31, 49, 50, 52] . However, the effects of increased integrindependent EC adhesion on angiogenesis are still elusive.
Integrins are regulated by distinct mechanisms: (a) the level of expression, (b) regulation of integrin affinity and integrin valency (avidity) and (c) integrin trafficking, which affects integrin localization in the cells and the assembly/disassembly of focal adhesions. Previous studies from our group provided insight in the regulation of integrin affinity in EC and their role in angiogenesis [6] . However, less is known about the mechanisms of integrin trafficking in EC and specifically their contribution to angiogenesis. Cell migration requires a tight spatiotemporal regulation of focal adhesion assembly and disassembly. Integrin trafficking (endocytosis/recycling) seems to be essential for cell migration by contributing to the turnover of focal and fibrillar adhesions during migration [8-10, 17, 53] .
Arf6 is a small GTPase cycling between an inactive GDP-and active GTP-bound form involved in the regulation of actin cytoskeleton and receptor trafficking [14, 19, 35] . Several stimuli, such as integrin binding to fibronectin, as well as stimulation with growth factors, cytokines and guidance molecules may induce the activation of Arf6 in EC [18, 20, 27, 44] . Arf6 can be activated by several guanine exchange nucleotide factors (GEFs) [7] . Brag2 (GEP100/IQSEC1) is a GEF activating the small ArfGTPases Arf4, Arf5 and Arf6 [33, 48] and is expressed in EC [20, 45] . Brag2 was found to promote the invasive activity of breast cancer cells [34] and myoblast fusion [11, 37] . Furthermore, Brag2 was shown to be involved in trafficking processes such as the endocytosis of synaptic AMPA-receptors, E-Cadherin recycling, and phagocytosis of monocytes [21, 46, 47] . Silencing of Brag2 in HeLa cells increased the surface expression of b1-integrins [15] and a later study indicated that Brag2 might contribute to b1-integrin endocytosis in HeLa cells [33] . However, the role of Brag2 in the regulation of integrins in EC was not studied thus far. In EC VEGF stimulation induces the association of VEGFR2 with Brag2 and induces the activation of Arf6 [20] . Interestingly, Semaphorin 3E-induced over-activation of the Brag2/Arf6 pathway results in collapse of EC and angiogenesis inhibition [45] . On the other side, it was demonstrated that silencing of Brag2 reduces endothelial tube formation in vitro and angiogenesis in a model of Angioreactor-induced angiogenesis [20] . Nevertheless, the role of Brag2 for in vivo physiological developmental and pathological angiogenesis and the underlying molecular mechanisms remain elusive.
In our present work, we provide direct evidence that Brag2 plays a key role in the regulation of integrin-dependent angiogenic functions such as sprouting, migration and adhesion of EC in vitro. Specifically, we show that Brag2 differentially affects b1-and aVb3-integrin function and promotes angiogenic sprouting by contributing to the endocytosis of b1-integrins, thereby Arf5-and Arf6-dependently regulating focal/fibrillar adhesions and reducing adhesion in EC. In accordance with these results, silencing of Brag2 impaired developmental angiogenesis and vascular patterning in zebrafish. Moreover, in vivo knockdown of Brag2 significantly reduced pathological angiogenesis in mice. Taking together, our work for the first time links a mechanism of integrin endocytosis with the process of angiogenesis.
Materials and methods

Cells
Human umbilical vein endothelial cells (HUVEC) were purchased from Lonza (Basel, Switzerland) and cultured in endothelial basal medium (EBM) supplemented with 1 lg/ mL hydrocortisone, 12 lg/mL bovine brain extract, 50 lg/ mL gentamicin, 50 ng/mL amphotericin-B, 10 ng/mL epidermal growth factor, and 10 % fetal calf serum until the third passage. Cos-7 cells were cultured in DMEM containing 10 % fetal calf serum.
RNAi transfections
To silence Brag2, a5-integrin, Arf5, Arf6 we performed transfection of small-interfering RNA (siRNA) duplex using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocol. Brag2 siRNAs were synthesized by Eurogentec and Sigma-Aldrich. The Brag2 target sequences were 5 0 -AGAACUCGGUGACGUACAG-3 0 (Brag2 siRNA-1), and 5 0 -GGAUGCAGUUCUCCUUU-GA-3 0 (Brag2 siRNA-2). A nonrelated scrambled siRNA was used as a control. The target sequence targeting a5-integrin is 5 0 -AATCCTTAATGGCTCAGACAT-3 0 (Qiagen). For silencing human Arf5 and Arf6, we used ONTARGETplus SMARTPool siRNAs and the respective controls from Dharmacon.
Plasmid constructs and transfection COS-7 cells (1.5 9 10 5 cells per 3.5 cm-well) were grown to 60-70 % confluence and then transfected with 4 lg plasmids using Superfect transfection reagent (QIAGEN) according to the manufacturer's protocol. The Brag2a-GFP (GEP100-GFP) plasmid was kindly provided by Dr. J.E. Casanova (Department of Cell Biology, University of Virginia Health System, Charlottesville, VA, USA). The Brag2a-DSec-GFP, Brag2a-DPH-GFP plasmids were kindly provided by Dr. M. Vaughan (Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, USA) and by Dr. A. Someya (Juntendo University, School of Medicine, Tokyo). The Arf5-GFP and Arf6-GFP were purchased by Addgene. Site-directed mutagenesis was performed to generate the rapid cycling Arf5-T161A-GFP and Arf6-T1571A-GFP mutants with the QuikChange II XL site-directed mutagenesis kit (Stratagene/Agilent, Waldbronn, Germany).
Spheroid-based angiogenic sprouting assay
Endothelial-cell spheroids were generated as described previously [6] . In brief, HUVEC were suspended in culture medium containing 0.2 % (w/v) carboxymethylcellulose (Sigma-Aldrich) 24 h after siRNA transfection and seeded in round-bottomed 96-well plates (Greiner) to form spheroids. The following day, spheroids were embedded into rat collagen I (BD Biosciences) containing gels. Angiogenic sprouting was stimulated where indicated by adding human vascular endothelial growth factor (VEGF, 50 ng/mL; PeproTech, Hamburg, Germany) containing medium after gel polymerization. In the experiments with the neutralizing integrin antibodies endothelial-cell spheroid embedded in the collagen gels were incubated with control antibody (BD Biosciences), anti-aVb3-integrin antibody (Clone LM609) or anti-b1-integrin antibody (clone: mAb13, BD Biosciences) in the presence of VEGF. After 24 h, images were acquired using an Axiocam MR digital camera with an Axiovert 100 M inverted microscope using as objective a Plan-NEOFLUAR (at 109/0.30) and were processed using AxioVision Rel 4.5 digital imaging software (all from Carl Zeiss, Jena, Germany). In vitro capillary sprouting was quantified by measuring the cumulative sprout length of each spheroid using a computer-assisted microscope [AxioVision 4.5 software (Carl Zeiss)] and the mean cumulative sprout length of 10 spheroids/condition was calculated.
Cell-matrix adhesion
Ninety-six-well plates were coated overnight with 1 lg/mL soluble recombinant human collagen I (Millipore) or 2.5 lg/mL human fibronectin (Sigma), 2.5 lg/mL human vitronectin (Millipore), or 2.5 lg/mL bovine serum albumin (BSA) in PBS at 4°C and then blocked for 1 h at room temperature with 3 % (w/v) heat-inactivated (2 h, 56°C) bovine serum albumin (BSA; Sigma-Aldrich). HUVEC were stained (48 h after the siRNA transfection) with 2 0 7 0 -bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF, AM; Molecular Probes) and after detachment with trypsin were resuspended in EBM containing 0.05 % BSA. Then, 50,000 cells/well were seeded and allowed to attach for 60 min at 37°C. After removal of non-adhering cells by washing with warm EBM, adherent cells were quantified in triplicates with a fluorescence plate reader (Synergy HT; Bio-Tek Instruments, Bad Friedrichshall, Germany). Data are presented as mean specific adhesion % of input ± SEM.
Zebrafish lines, morpholinos and vessel quantification
Embryos of AB wt and the tg(fli1:EGFP) line were raised and staged as described [30] . Embryos were kept in E3 solution at 28.5°C with or without 0.003 % 1-phenyl-2-thiourea (Sigma) to suppress pigmentation and staged according to somite number or hours post-fertilization [16] . Morpholinos were diluted in 0.1 M KCl and 1 nL of morpholino dilution was injected through the chorion of one-cell or two-cell stage embryos. To attenuate possible off-target effects, a p53 Mo was co-injected 1.5-fold to the other morpholinos used. The following splice-blocking morpholinos (Gene Tools) were used: Quantification of vessel defects in tg(fli1:EGFP) embryos of intersomitic vessels (ISV) and the dorsal longitudinal anastomotic vessel (DLAV) was performed as recently described [16] . Parachordal vessel/parachordal lymphangioblasts (PL) were quantified as recently described [16] . In brief, embryos were divided in three groups according to the presence (2), partial (1) or complete absence (0) of the parachordal lymphangioblasts. For the quantification of CCV defects following criteria were used: 2-broad, all cells have intercellular contacts to each other and are homogenously regular distributed, not branched; 1-thin vessel, branched, not all cells have contacts to each other and as consequence there exist gaps between cells; 0-very thin or interrupted vessel, shortened vessel with brittle structure.
In the experiments of the Supplemental Figure S6 following conditions were compared in order to exclude offtarget effects of double injections of morpholinos: All animal experiments were approved by the Animal Care and Use Committee at the NEI/National Institutes of Health (NIH) and were performed according to the NIH guidelines and regulations. Briefly, 7-day-old (p7) C57BL/ 6J mice were exposed to 75 % oxygen in a chamber for 5 days with their nursing mothers. At p12, the mice were returned to room air. Brag2 shRNA vector (TRCN0000340707, Open Biosystems) or the control vector PLKO.1 (Sigma) was delivered to the eyes of anesthetized neonatal mice by intravitreal injections with the in vivo-jetPEI TM reagent (Polyplus Transfection) at p12. The eyes with severe vitreous hemorrhage or disturbed development after injection were excluded from assessment. Mice were euthanized and the eyes harvested at P17. Whole-mount retinae were stained with Isolectin GS-IB4 Alexa Fluor Ò 488 (Invitrogen). Image analysis was performed using a Carl Zeiss Imager Z1 and the imageprocessing software: AxioVision (Carl Zeiss), Photoshop CS (Adobe). Quantification of neovascularization was performed as previously described [13] .
In the model of laser-induced choroidal neovascularization female mice (age 6 weeks) were used for experiments. Four laser spots were introduced (75 lm spot size, 75 ms, 90 mW power; OcuLight Infrared Laser System 810 nm, Iridex) in the area surrounding the optic disk in the eye. Mouse Brag2 shRNA (2 lg/eye, Open Biosystems, catalogue number TRCN0000340707) or PLKO1 empty plasmid was injected intravitreally 2 days before laser treatment together with the transfection reagent in vivo-jetPEI TM (Polyplus Transfection, New York, NY) according to the manufacturer's instructions. The CNV area was analyzed at 1 week after laser treatment using isolectin B4 (IB4, Invitrogen) staining. For eye tissue (choroid and retina) isolation, the anterior segment and the vitreous of the eyes were removed. The retina was dissected from the RPE-choroid eye cup. The dissected tissues were fixed for morphological analysis.
Statistical analysis
Continuous variables are expressed as mean ± SEM or where indicated mean ± SD. Comparisons between groups were analyzed by t test (2-sided) or analysis of variance (ANOVA) (post hoc test: Newman-Keuls) for experiments with more than 2 subgroups (GraphPad Prism version 5.0). In the zebrafish experiments the Kruskal-Wallis test was used. P values\0.05 were considered statistically significant.
Results
Role of Brag2 in the VEGF-induced activation of Arf6
Consistent with previous studies [20, 45] HUVEC and human microvascular endothelial cells express Brag2a and Brag2b protein as assessed by Western blot (data not shown). Moreover, we confirmed that VEGF stimulation rapidly increases the activity of the small GTPase Arf6 in EC (supplemental Figures S1A and S1B) as previously reported [18, 20, 27] . To address the role of Brag2 as guanine nucleotide exchange factor (GEF) in the VEGFinduced activation of Arf6, we employed siRNA targeting Brag2. Silencing of Brag2 with siRNAs effectively reduced the expression of Brag2 mRNA and protein (supplemental Figures S1C and S1D) while not significantly affecting the expression of other Arf6 GEFs such as Cytohesin-1, Cytohesin-2 and Cytohesin-3 (data not shown). Furthermore, silencing of Brag2 reduced basal and VEGF-induced activation of Arf6 (supplemental Figures S1A and S1B). Thus, Brag2 is required for Arf6 activation under basal conditions and upon VEGF stimulation. Likewise, Semaphorin 3E also activates Arf6 in a Brag2-dependent manner; however, the Semaphorin 3E-induced Arf6-activation is delayed and much more sustained ( [44] and data not shown).
Role of Brag2 for angiogenic sprouting, tube formation and EC migration
We next explored the contribution of endogenous Brag2 in angiogenesis in vitro. Silencing of Brag2 with siRNA significantly reduced the capability of 3-dimensional EC spheroids of angiogenic sprouting in the presence or absence of VEGF (Fig. 1a, b ) or bFGF (data not shown) in comparison to scrambled siRNA-transfected HUVEC. As a control for the specificity of this approach, a second Brag2-siRNA was generated and gave similar results (Fig. 1a , and supplemental Figures S1C and S1D). Moreover, transient overexpression of Brag2a-GFP rescued the inhibition of angiogenic sprouting exerted by a siRNA targeting the 3 0 UTR region of Brag2 (data not shown). In accordance with these data, silencing of Brag2 significantly impaired tube/network-forming activity of HUVEC in the matrigel assay ( Fig. 1c, d ). Furthermore, Brag2 silencing significantly impaired the VEGF-induced 3-dimensional invasion and the 2-dimensional migration of HUVEC on fibronectin in a scratch wound assay (Fig. 2a, b) , while not significantly affecting HUVEC proliferation (Supplemental Figure S1E ). Taken together, Brag2 is essential for in vitro angiogenesis and EC migration.
Brag2 differentially regulates b1-and aVb3-integrins
The regulation of integrin-mediated cell adhesion on matrix proteins is essential for cell migration [42] . Therefore, we studied the role of Brag2 in the b1-integrin- dependent EC adhesion on ECM proteins such as fibronectin and collagen. Interestingly, silencing of Brag2 significantly enhanced the steady-state b1-integrin-dependent HUVEC adhesion on fibronectin and collagen and significantly increased spreading (cell area) on fibronectin in comparison to scrambled siRNA-transfected HUVEC ( Fig. 2c-e) . Remarkably, the effect on adhesion seems to be specific for the b1-integrins since silencing of Brag2 e Spreading assay of HUVEC on fibronectin 48 h after transfection with scrambled or Brag2 siRNA. Data are presented as mean cell area ± SEM (*P \ 0.05 vs. scrambled siRNA, n = 3). f, g Immunofluorescence staining for b1-integrin (f) or active a5-integrin subunit (clone SNAKA51) (g) in HUVEC adhering on fibronectin, 48 h after transfection with scrambled siRNA or Brag2 siRNA. Microphotographs demonstrating focal and fibrillar adhesions were acquired at the basal surface of the cells, where focal/fibrillar adhesions are localized. Red fluorescence indicates the active a5-integrin or b1-integrin subunit, green fluorescence indicates phalloidin staining for F-actin and white color indicates nuclei. The white arrows indicate focal and fibrillar adhesions significantly reduced HUVEC adhesion on the b3-integrin ligand, vitronectin (supplemental Figure S1F ). In accordance with these results, silencing of Brag2 increased b1-integrinand active a5-integrin-containing focal and fibrillar adhesions and enhanced the formation of actin stress fibers in HUVEC adhering on fibronectin, suggesting that Brag2 is a negative regulator of b1-integrin-containing focal/fibrillar adhesions (Fig. 2f, g ). Quantification of the focal/fibrillar adhesion area by performing immunofluorescent staining with an antibody recognizing activated/matrix-bound a5b1-integrins localized in fibrillar and partly in focal adhesions (clone SNAKA51) [12] confirmed these results ( Fig. 2g and Supplemental Figure S1G ). These data raised the hypothesis that Brag2 may contribute to the disassembly of b1-integrincontaining focal/fibrillar adhesions in EC.
Silencing of Brag2 increases a5b1-integrinand reduces aVb3-integrin surface expression on EC
To understand the differential function of Brag2 in EC adhesion, we determined the role of Brag2 for the cell surface expression of b1-and aVb3-integrins. Indeed, silencing of Brag2 by siRNA increased the cell surface abundance of the a5b1-integrin on HUVEC as assessed by FACS (Fig. 3a) , while not affecting the total a5-integrin and b1-integrin protein expression as assessed by Westernblot (Supplemental Figures S2A and S2B ). In addition, silencing of Brag2 also slightly increased the expression of a3b1-and a6b1-integrin on the EC surface (data not shown). In contrast, knockdown of Brag2 significantly reduced the surface expression of the aVb3-integrin 
(Supplemental Figures S2C and S2D) , which is in accordance with the reduction of EC adhesion to the aVb3-integrin ligand, vitronectin (supplemental Figure S1F) . Thus, silencing of Brag2 differentially affects b1-and b3-integrin expression on the EC surface and adhesion on fibronectin and vitronectin.
Brag2 promotes angiogenesis by regulating of a5b1-integrin expression on the EC surface b1-integrin inhibition with neutralizing antibodies significantly blocked angiogenic sprouting of HUVEC, while aVb3-integrin inhibition did not (Supplemental Figure  S1H ). In line with these results, genetic evidence supports that b1-integrins are essential for in vivo angiogenesis [3, 4, 41, 49, 52] . Since silencing of Brag2 enhanced b1-integrin-dependent adhesion and a5b1-integrin surface expression, we investigated the underlying mechanisms affecting b1-integrin function in EC. Specifically, we addressed the role of the enhanced surface expression of a5b1-integrins for the inhibitory effect of Brag2 silencing on angiogenic sprouting. For this purpose, we performed silencing of a5-integrin subunit of the a5b1-integrin using a low dose of siRNA in Brag2 siRNA-transfected HUVEC, in order to achieve a slight reduction of the a5-integrin on the cell surface reaching the levels observed in scrambled siRNA-transfected EC as assessed by FACS (Fig. 3b) . Strikingly, a reduction of the a5b1-integrin surface abundance in the Brag2-siRNA-transfected HUVEC partly rescued the inhibitory effect of Brag2 silencing on angiogenic sprouting (Fig. 3b, c) . Hence, Brag2 partly mediates Data are presented as specific mean fluorescence intensity % of siScr ± SEM (*P \ 0.05 vs. siScr, n = 8). c Spheroidal sprouting assays using HUVEC transfected with scrambled siRNA (siScr), Brag2 siRNA (siBrag2) or Brag2 siRNA and low-dose ITGA5 siRNA (siBrag2 ? low-dose siITGA5) were performed. The mean cumulative length of sprouts per spheroid was assessed after 24 h. Data are presented as mean cumulative length of sprouts per spheroid ± SEM (*P \ 0.05, siBrag2 vs. siBrag2 ? low-dose siITGA5, n = 7)
c Fig. 4 Brag2 mediates b1-integrin internalization. a Immunofluorescent staining for Brag2 (green fluorescence) and activated/matrixbound a5b1-integrin (clone SNAKA51) present in focal and fibrillar adhesions. The blue color indicates nuclear staining (DAPI). The white arrow indicates Brag2 co-localized or in the vicinity of focal/ fibrillar focal adhesions. TIRF microscopy with a 9100 objective was performed, in order to assess the co-localization in the basal level of HUVEC. b Pulse-chased endocytosis assay based on immunofluorescence staining for b1-integrin subunit in HUVEC adhering on fibronectin, 48 h after transfection with scrambled siRNA or Brag2 siRNA. HUVEC were allowed to internalize b1-integrin for 10 min as described in the ''Materials and methods''. Red fluorescence indicates the internalized b1-integrin subunit, green fluorescence indicates phalloidin staining for F-actin and white color indicates nuclei. c Pulse-chased endocytosis assay of the b1-integrin subunit in HUVEC as determined with FACS as described in the ''Materials and methods'' section. Data are presented as mean internalized b1-integrin % of total surface b1-integrin ± SEM (*P \ 0.05 vs. scrambled siRNA, n = 6). d, e Biochemical biotinylation-based internalization assay of b1-integrin (d) and of activated a5-integrin subunit (e) were performed for the indicated time-points (0, 5 and 15 min) as described in the ''Materials and methods'' section. Data are presented as mean internalized integrin % of total surface integrin ± SEM (*P \ 0.05 vs. scrambled siRNA at 15 min of endocytosis, n = 3)
angiogenic sprouting by regulating the surface expression of the a5b1-integrin on the EC surface. Remarkably, silencing of the a5-integrin subunit employing a high dose of a5-integrin-siRNA leading to a profound reduction of the a5-integrin on the EC surface significantly blocked in vitro angiogenic sprouting (Supplemental Figure S2E) suggesting that a tight regulation of b1-integrin surface expression is essential for efficient angiogenic sprouting.
Brag2 promotes endocytosis of b1-integrins and recycling of aVb3-integrins in EC
As assessed by TIRF microscopy, Brag2 partly co-localized with focal/fibrillar adhesions containing activated a5b1-integrins indicating a direct role of Brag2 in the regulation of focal/fibrillar adhesions (Fig. 4a) . Mechanisms of endocytosis were shown to contribute to the disassembly of focal adhesions during cell migration [8] [9] [10] 17] . Therefore, we hypothesized that Brag2 may mediate endocytosis/internalization of b1-integrins in EC. Silencing of Brag2 with siRNA significantly reduced the internalization of the b1-integrin as assessed by a pulse-chased immunofluorescencebased endocytosis assay (Fig. 4b) . To quantify the internalization of b1-integrins, we additionally employed a FACS-based endocytosis assay (Fig. 4c) . Indeed, silencing of Brag2 with siRNA significantly reduced b1-integrin internalization (Fig. 4c) . Since binding of antibodies to surface receptors and cell detachment by trypsin may affect internalization rates of surface receptors, we also employed a biochemical internalization assay based on biotinylation of surface proteins [43, 53] . Indeed, silencing of Brag2 significantly reduced the internalization of the b1-integrin subunit in comparison to scrambled siRNA-transfected HUVEC (Fig. 4d) . Since silencing of Brag2 increased focal/fibrillar adhesions in HUVEC adhering to the a5b1-integrin ligand fibronectin (Fig. 2f, g ) and since focal and fibrillar adhesions contain activated (matrix-bound) integrins [2] , we also specifically explored the role of Brag2 for the internalization of activated/matrix-bound a5b1-integrin by using an antibody, which recognizes activated a5b1-integrins localized in fibrillar and partly in focal adhesions (clone SNAKA51) [12] . Silencing of Brag2 significantly reduced the internalization of activated a5b1-integrins (Fig. 4e) . Interestingly, silencing of Brag2 reduced the internalization of activated a5b1-integrins even in the presence of the recycling inhibitor primaquine, suggesting that Brag2 is mediating internalization without affecting recycling of activated a5b1-integrin (data not shown). In summary, our data indicate that Brag2 may promote EC migration and angiogenesis by mediating b1-integrin endocytosis thereby contributing to the turnover of focal/fibrillar adhesions and regulating b1-integrin-dependent EC adhesion. Interestingly, silencing of Brag2 did not significantly affect endocytosis of aVb3-integrins (data not shown), but significantly reduced their recycling (Supplemental Figure S2F ). Taking together, Brag2 mediates endocytosis of b1-integrins and recycling of aVb3-integrins.
Brag2 promotes endocytosis of b1-integrins in EC and angiogenic sprouting in an Arf-GTPase-dependent manner
To gain insight in the molecular mechanisms involved in Brag2-mediated b1-integrin endocytosis, we studied the domains of Brag2 required in this process. Therefore, we overexpressed following constructs in COS7 cells: WTBrag2a-GFP, Brag2a-DSec-GFP lacking the catalytic domain Sec7, which is essential for the activation of GTPases of the Arf family, Brag2a-DPH-GFP lacking the pleckstrin homology domain, which is required for the activation of the enzymatic activity of Brag2 by binding PI(4,5)P2 on membranes [26, 45] , or EGFP control vector and assessed b1-integrin endocytosis in a pulse-chased endocytosis assay by FACS in GFP ? cells. Overexpression of WT-Brag2a-GFP increased the internalization of b1-integrin in comparison to EGFP-transfected COS7 cells (Fig. 5a) . Overexpression of Brag2a-DSec7-GFP or b Fig. 5 Role of Arf GTPases for Brag2-mediated b1-integrin internalization, angiogenic sprouting and regulation of focal/fibrillar adhesions. a Pulse-chased endocytosis assay of the b1-integrin subunit in COS7 cells as determined with FACS. Briefly, Cos7 cells were transfected with wild-type Brag2a-GFP, Brag2a-DSec-GFP, Brag2a-DPH-GFP or EGFP empty vector. After 24 h, a pulse-chased endocytosis assay of the b1-integrin subunit was performed for 10 min and the MFI of internalized b1-integrin was determined in GFP ? COS7 cells by FACS. Data are presented as mean internalized b1-integrin % of total surface b1-integrin ± SEM (*P \ 0.05 vs. EGFP; # P \ 0.05 vs. GFP-Brag2a, n = 7). b HUVEC were transfected with scrambled or Brag2 siRNA. After 24 h, cells were transiently transfected where indicated with EGFP empty vector, rapid cycling Arf5-T161A-GFP mutant, or a rapid cycling Arf6-T157A-GFP mutant. After 24 h, immunofluorescent staining was performed with an antibody recognizing activated/matrix-bound a5b1-integrin (clone SNAKA51) present in focal and fibrillar adhesions. The focal adhesion area in GFP ? and GFP -cells of each condition was quantified by confocal microscopy. Data are presented as focal adhesion area % total cell area ± SEM (*P \ 0.05 vs. siBrag2 ? EGFP-GFP ? and siBrag2 ? Arf5-T161A-EGFP-GFP -; n = 3-4). c Representative images for Brag2a-DPH-GFP did not promote the endocytosis of b1-integrins (Fig. 5a ), indicating that Brag2 is mediating endocytosis of b1-integrins by activation of Arf-GTPases. Consistent with these results, overexpression of the rapid cycling mutant Arf5-T161A-GFP significantly reduced the increased SNAKA51-positive focal/fibrillar adhesions observed upon silencing of Brag2 (Fig. 5b, c) . Moreover, also the rapid cycling mutant Arf6-T157A-GFP reduced, even if not significantly, focal/fibrillar adhesions induced by Brag2-silencing (Fig. 5b, c) 
Role of Brag2 for developmental angiogenesis in zebrafish
Having demonstrated that Brag2 regulates in vitro angiogenesis, EC migration and matrix adhesion, we next explored whether Brag2 contributes to endothelial sprouting and vessel formation in vivo. For this purpose, we studied the effect of Brag2/IQSEC1 silencing during embryonic development of zebrafish in the transgenic tg(fli1:EGFP) zebrafish line expressing EGFP in vessels under control of the fli-1 promoter. We identified 2 orthologue IQSEC1 genes (Brag2/GEP100) in zebrafish using the ENSEMBL database: ENSDARG00000016551 (IQSEC1a) and ENSDARG00000073822 (IQSEC1b). RT-PCR of FACS-sorted EGFP-positive EC from the developing tg(fli1:EGFP) zebrafish at 24hpf [51] revealed that IQSEC1a and IQSEC1b mRNA are present in EC in zebrafish yielding a band of 367 and 403 bp, respectively (Supplemental Figure S3) . To determine the role of these genes in developmental angiogenesis, we designed specific splice-blocking morpholinos targeting these genes. Knockdown of IQSEC1a or IQSEC1b or both was achieved by injection of splice-blocking morpholinos resulting in an aberrant splicing of the IQSEC1a and IQSEC1b mRNA, respectively (Supplemental Figure S4A and S4B) . Silencing of IQSEC1a using the splice-blocking IQSEC1a-MO-A morpholino led to vascular defects in 48hpf old tg(fli1:EGFP) zebrafish embryos. Specifically, silencing of IQSEC1a significantly induced defects of the dorsal longitudinal anastomotic vessel (DLAV) and intersomitic vessels (ISV) (Fig. 6a, c, d ) and significantly reduced the formation of the parachordal lymphangioblasts (PL), the precursor to the lymphatic system at 48hpf and 72hpf (Fig. 6e, Supplemental figure S6C and S6D) . For a control of the specificity of the IQSEC1a-MO-A morpholino, we designed a second splice-blocking morpholino (IQSEC1a-MO-B) silencing IQSEC1a expression, which led to similar results in the vasculature in tg(fli1:EGFP) embryos (Fig. 6a, c-e and Supplemental Figure S6A , S6B, S6C and S6D). Silencing of IQSEC1b with two distinct spliceblocking morpholinos (IQSEC1b-MO-A and IQSEC1b-MO-B) led to a milder vascular phenotype. Specifically, silencing of IQSEC1b only significantly impaired formation of the parachordal vessel/parachordal lymphangioblast (PL) at 48hpf and 72hpf (Fig. 6e, Supplemental Figures  S6C and S6D ) but did not significantly affect the formation of ISV and DLAV (Fig. 6a, Supplemental figures S6A and  S6B) . Strikingly, silencing of both IQSEC1a and IQSEC1b led to a more severe vascular phenotype strongly affecting vascular patterning in tg(fli1:EGFP) zebrafish embryos (Fig. 6b) . Indeed, silencing of IQSEC1a and IQSEC1b genes induced more severe defects in the ISV and in the DLAV (Fig. 6b-d ) and led to a highly penetrant absence of the PL (Fig. 6e) . In addition, silencing of both genes, IQSEC1a and IQSEC1b, led to defects in the formation of the common cardinal vein (CCV) in tg(fli1:EGFP) zebrafish embryos at 48hpf (Fig. 6f, g ). Remarkably, silencing of both genes, IQSEC1a and IQSEC1b also led to vascular edema in the tail and to formation of hydrocephalus (Supplemental Figure S5A and Figure S5B ). Taken together, the Brag2 orthologue genes IQSEC1a and IQSEC1b play an essential synergistic role in the developmental angiogenesis of the zebrafish and in vessel stability and affect vascular patterning.
Inhibition of Brag2 in vivo reduces pathological angiogenesis in mice
Next, we attempted to address whether Brag2 is also involved in pathological angiogenesis. The ROP model mimics the ischemia-induced angiogenesis observed in retinopathy of prematurity. Intravitreal injection of Brag2 shRNA reduced the in vivo expression of murine Brag2 by 73.5 % as assessed by qPCR (Supplemental Figure S7) . Intravitreal injection of Brag2 shRNA significantly inhibited retinal neovascularization in comparison to empty vector (Fig. 7a, b) . In addition, laser-induced choroidal neovascularization is a disease model of the wet form of age-related macular degeneration. In this model, a laser is used to disrupt the Bruch's membrane leading to the invasion of the choroidal vasculature into the subretinal pigment epithelium. Injection of Brag2 shRNA led to a significant reduction of choroidal neovascularization in comparison to mice treated with the control vector (Fig. 7c , 
Discussion
The present study underscores the relevance of Brag2 for regulation of integrin function in EC and in angiogenesis. Specifically, our findings revealed that: (1) endothelial Brag2 mediates migration and in vitro angiogenic sprouting in an Arf-GTPase-dependent manner partly by regulating the surface expression of a5b1-integrins; (2) Brag2 differentially regulates a5b1-and aVb3-integrins in EC. Specifically, Brag2 promotes the endocytosis of active/ matrix-bound a5b1-integrins, thereby regulating a5b1-integrin abundance on the cell surface, contributing to the turnover of focal adhesions, and reducing b1-integrindependent adhesion. In contrast, Brag2 promotes the recycling of aVb3-integrins, thereby increasing aVb3-integrin cell surface abundance and promoting EC adhesion on the aVb3-integrin ligand vitronectin; (3) Brag2 genes (IQSEC1a and IQSEC1b) are essential for developmental angiogenesis in zebrafish, thereby contributing to vascular patterning and finally; (4) inhibition of Brag2 in vivo reduces pathological retinal angiogenesis and choroidal neovascularization. Thus, the present study provides insights into the mechanisms of integrin endocytosis in EC and their contribution to the process of angiogenesis and unravels a novel function of Brag2 as key mediator of physiological and pathological neovascularization. Moreover, inhibition of Brag2 seems to be a promising therapeutic target for treatment of pathological angiogenesis.
Adhesion to fibronectin and VEGF was shown to stimulate activation of the Arf6 GTPase [18, 20, 27 ]. Our present work shows that Brag2 is required for basal and VEGF-induced Arf6 activity in EC. These data are consistent with the data of Hashimoto et al. [20] demonstrating that VEGF stimulation leads to the association of VEGFR2 to Brag2 thereby mediating Arf6 activation. Interestingly, a pharmacological inhibitor of the Arf6-GEFs cytohesins 1-3, SecinH3, reduced VEGF-induced activation of Arf6 in EC [27] , suggesting that not only Brag2, but also Arf6-GEFs of the cytohesin family may contribute to the VEGF-induced stimulation of Arf6 activity.
Remarkably, silencing of Brag2 blocked angiogenic sprouting and tube-forming activity of EC. In line with these results, knock down of the orthologue genes of Brag2 (IQSEC1a and/or IQSEC1b) in zebrafish perturbed developmental angiogenesis and vascular patterning. Interestingly, silencing of IQSEC1a and IQSEC1b also impaired the formation of the parachordal vessel/parachordal lymphangioblasts, which is considered as a precursor of the lymphatic system [55] and additionally led to vascular edema and hydrocephalus. Beyond developmental angiogenesis, in vivo silencing of Brag2 significantly reduced pathological angiogenesis in the disease model of retinopathy of prematurity and in the model of choroidal neovascularization. Consistent with our results, also in a model of Angioreactor-induced angiogenesis, silencing of Brag2 inhibited neovascularization [20] . Furthermore, the pharmacological inhibition of Arf6-GEFs of the cytohesin family with SecinH3 reduced angiogenesis [27] . Intriguingly, not only inhibition but also an over-activation of the Brag2/Arf6 pathway, as achieved by stimulation with Semaphorin 3E, blocks angiogenesis [44, 45] . In conclusion, a stringent and balanced activation of Arf-GTPases by Brag2 is mandatory for efficient angiogenesis.
A relevant question is how Brag2 promotes angiogenesis. EC migration is essential for angiogenesis. We found that Brag2 promotes 2-and 3-dimensional EC migration, while not affecting proliferation. Cell migration requires the dynamic establishment of new integrin-mediated focal adhesions by binding of integrins to ECM proteins in the migrating front, concomitant with the disassembly/turnover of mature focal/fibrillar adhesions allowing cell retraction and forward movement [8, 9] . Integrin trafficking is involved in the assembly/disassembly of focal/fibrillar adhesions. Indeed, focal/fibrillar adhesion disassembly includes the internalization/endocytosis of integrins [8-10, 17, 53] . Strikingly, we provide here direct evidence that Brag2 partly mediates angiogenesis by reducing a5b1-integrin surface expression. Specifically, we show that Brag2 promotes b1-integrin endocytosis in EC, thereby reducing focal/fibrillar adhesions and EC adhesion to b1-integrin ligands. In addition, silencing of Brag2 also slightly increased a3b1-and a6b1-integrin on the EC surface (data not shown). In line with our results, Dunphy et al. [15] demonstrated that silencing of Brag2 in HeLa cells increased surface expression of b1-integrins and cell spreading. Moreover, another study suggested that Brag2 may promote b1-integrin endocytosis [33] . Remarkably in our present work, we demonstrated that Brag2 is involved in the internalization/endocytosis of activated (matrix-bound) a5b1-integrins, as assessed by an activationdependent a5b1-integrin antibody recognizing an active a5b1-integrin conformation present in fibrillar and partly in focal adhesions [12] , supporting the idea that Brag2 contributes to the disassembly of focal/fibrillar adhesions by mediating endocytosis of active/matrix-bound a5b1-integrins. Interestingly, silencing of Brag2 also reduced the recycling of aVb3-integrins to the cell surface and consequently decreased the cell surface expression of aVb3-integrins and adhesion to vitronectin. However, in our hands inhibition of aVb3-integrins (in contrast to b1-integrin inhibition) did not affect angiogenic sprouting. In summary, our data indicate that Brag2 promotes EC migration and angiogenesis by mediating b1-integrin endocytosis thereby contributing to the turnover of focal/fibrillar adhesions and regulating a5b1-integrin-dependent EC adhesion.
An important question is how Brag2 mediates integrin endocytosis. In this regard, we found that the integrin endocytosis-promoting activity of Brag2 is dependent on the activation of Arf-GTPases. However, the effector proteins downstream of Arf-GTPases signaling mediating integrin internalization in EC are unclear. Arf6 was shown to contribute via PIP5K and recruitment of AP2 and clathrin to receptor endocytosis [22, 29, 39] . Moreover, a recent study demonstrated that Brag2 could bind clathrin and AP2 itself and that Arf5, an Arf-GTPase also activated by Brag2, may contribute to b1-integrin endocytosis [33] . In line with these results, we found here that Arf5 and Arf6 mediate downstream of Brag2 angiogenic sprouting and the regulation of focal/fibrillar adhesions containing activated a5b1-integrins in EC. Interestingly, it was shown that Arf6 may also mediate recycling of b1-integrins to the cell surface [40] . Additional studies are mandatory in order to define the downstream mechanisms promoting Brag2-dependent integrin endocytosis.
An additional mechanism by which Brag2 may affect angiogenesis includes the regulation of vascular permeability. Indeed, silencing of Brag2 increases in vitro permeability of EC monolayers ( [20] and our unpublished data), while reducing the surface abundance of VE-Cadherin [20] . Moreover, silencing of Brag2 (IQSEC1a and IQSEC1b) in zebrafish led to hydrocephalus and vascular edema, probably as a consequence of vascular hyperpermeability. Nevertheless, the permeability regulating activity of Brag2 does not explain the observed inhibition of EC migration and angiogenic sprouting induced by the knockdown of Brag2 in our study. Indeed, VE-Cadherin-induced cell-cell interactions were shown to block EC migration and angiogenic sprouting [1] . So, one would expect that, since silencing of Brag2 reduces VE-Cadherin-mediated cell-cell adhesion (adherens junctions) and increases vascular permeability ( [20] and our unpublished data), would rather lead to a promigratory and proangiogenic EC phenotype. However, as we clearly demonstrated in our present work silencing of Brag2 blocked angiogenic sprouting, EC migration and in vivo angiogenesis. Furthermore, specifically Arf6 was shown to modify VEGFR2 function in endothelial cells [25] . However, silencing of Brag2 did not reduce VEGF-induced VEGFR2 phosphorylation and Akt activation (data not shown), suggesting that the inhibitory effect of Brag2 knockdown on angiogenic sprouting cannot be ascribed to an inhibition of VEGFR2-induced signaling. Surprisingly, Brag2 exerted opposing effects on b1-and b3-integrins in EC. A potential explanation for these opposing effects is that the trafficking of a5b1-and aVb3-integrins are inversed coupled to each other [54] . However, additional studies will be required to clarify the underlying molecular mechanisms in EC. Based on the fact that b1-integrins are essential for angiogenesis [4, 49, 52] , we focused in the present study on the effects of Brag2 on b1-integrins in EC.
Taken together, our data demonstrate that Brag2 is a key mediator of developmental and pathological angiogenesis by promoting b1-integrin endocytosis thereby regulating b1-integrin-containing focal/fibrillar adhesions, and consequently EC migration and sprouting. Thus, our present work provides evidence that mechanisms involved in integrin endocytosis are essential in angiogenesis and that increased EC adhesion as a consequence of reduced integrin endocytosis may negatively affect angiogenesis. In line with our results, Palecek et al. [38] demonstrated that high cell-substratum adhesiveness impairs cell motility, and that maximum cell speed occurs at intermediate adhesiveness. Since silencing of Brag2 did not completely abolish b1-integrin internalization in EC, additional pathways may also contribute to this process as reported elsewhere [36, 53] . Finally, Brag2 inhibition seems to be a promising target for the development of new antiangiogenic approaches to treat patients with pathological angiogenesis such as in proliferative retinopathies and in cancer.
